Samsung Biologics Co.,Ltd. (KRX:207940)

Samsung Biologics Revenue

Samsung Biologics had revenue of 1.29T KRW in the quarter ending June 30, 2025, with 11.50% growth. This brings the company's revenue in the last twelve months to 5.03T, up 19.48% year-over-year. In the year 2024, Samsung Biologics had annual revenue of 4.55T with 23.08% growth.

• Revenue (ttm): 5,031.69B
• Revenue Growth: +19.48%
• P/S Ratio: 14.16
• Revenue / Employee: 996.97M
• Employees: 4,770
• Market Cap: 71.25T

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	4,547.32B	852.73B	23.08%
Dec 31, 2023	3,694.59B	693.29B	23.10%
Dec 31, 2022	3,001.30B	1,433.29B	91.41%
Dec 31, 2021	1,568.01B	403.23B	34.62%
Dec 31, 2020	1,164.78B	463.19B	66.02%